Saturday 17 October 2026
Export AKAN’s income statement to Excel — free account
Akanda Corp.
AKAN Healthcare Drug Manufacturers Specialty & Generic
Akanda Corp.’s revenue for fiscal 2025 (year ended December 2025) was $258,100.00, down 69.2% from fiscal 2024. Insiders bought in the last twelve months.
1.20
0.11
−8.40%
Follow AKAN
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+7 more TTM periods Free account |
0.00% | 0.00% | 0.00% | 0.00% | |
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow |
(12.32) | (8.45) | (18.24) | — | |
Capital Expenditures |
(3.33) | — | (4.57) | — | |
| Other line items | |||||
Cash ROIC |
(145.41%) | (138.82%) | (1,209.79%) | 0.00% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
3.04 | 2.10 | 0.17 | 0.00 | |
Capex/Depreciation |
(0.46) | 0.00 | (3.54) | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | — | |
Capex per Share |
0.00 | — | 0.00 | — | |
Capex to Sales |
0.00 | — | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026